273 related articles for article (PubMed ID: 22924434)
21. Lysine acetylation and cancer: A proteomics perspective.
Gil J; Ramírez-Torres A; Encarnación-Guevara S
J Proteomics; 2017 Jan; 150():297-309. PubMed ID: 27746255
[TBL] [Abstract][Full Text] [Related]
22. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
23. Small molecules as tools to study the chemical epigenetics of lysine acetylation.
Schiedel M; Conway SJ
Curr Opin Chem Biol; 2018 Aug; 45():166-178. PubMed ID: 29958150
[TBL] [Abstract][Full Text] [Related]
24. A chemical toolbox for the study of bromodomains and epigenetic signaling.
Wu Q; Heidenreich D; Zhou S; Ackloo S; Krämer A; Nakka K; Lima-Fernandes E; Deblois G; Duan S; Vellanki RN; Li F; Vedadi M; Dilworth J; Lupien M; Brennan PE; Arrowsmith CH; Müller S; Fedorov O; Filippakopoulos P; Knapp S
Nat Commun; 2019 Apr; 10(1):1915. PubMed ID: 31015424
[TBL] [Abstract][Full Text] [Related]
25. Selective recognition of acetylated histones by bromodomains in transcriptional co-activators.
Hassan AH; Awad S; Al-Natour Z; Othman S; Mustafa F; Rizvi TA
Biochem J; 2007 Feb; 402(1):125-33. PubMed ID: 17049045
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300.
Zeng L; Zhang Q; Gerona-Navarro G; Moshkina N; Zhou MM
Structure; 2008 Apr; 16(4):643-52. PubMed ID: 18400184
[TBL] [Abstract][Full Text] [Related]
27. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
28. Bromodomains: Translating the words of lysine acetylation into myelin injury and repair.
Ntranos A; Casaccia P
Neurosci Lett; 2016 Jun; 625():4-10. PubMed ID: 26472704
[TBL] [Abstract][Full Text] [Related]
29. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
30. Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors.
Zhang F; Ma S
Curr Drug Targets; 2018; 19(10):1148-1165. PubMed ID: 29189147
[TBL] [Abstract][Full Text] [Related]
31. Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.
Lori L; Pasquo A; Lori C; Petrosino M; Chiaraluce R; Tallant C; Knapp S; Consalvi V
PLoS One; 2016; 11(7):e0159180. PubMed ID: 27403962
[TBL] [Abstract][Full Text] [Related]
32. A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications.
Flynn EM; Huang OW; Poy F; Oppikofer M; Bellon SF; Tang Y; Cochran AG
Structure; 2015 Oct; 23(10):1801-1814. PubMed ID: 26365797
[TBL] [Abstract][Full Text] [Related]
33. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
34. Binding Mode of Acetylated Histones to Bromodomains: Variations on a Common Motif.
Marchand JR; Caflisch A
ChemMedChem; 2015 Aug; 10(8):1327-33. PubMed ID: 26033856
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of Nε-acetyl-L-homolysine by the Lossen rearrangement and its application for probing deacetylases and binding modules of acetyl-lysine.
Rehkopf L; Seidel J; Sindlinger J; Wang M; Kirchgäßner S; Schwarzer D
J Pept Sci; 2023 Apr; 29(4):e3462. PubMed ID: 36416071
[TBL] [Abstract][Full Text] [Related]
36. Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor.
Dutra LA; Heidenreich D; Silva GDBD; Man Chin C; Knapp S; Santos JLD
Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077030
[TBL] [Abstract][Full Text] [Related]
37. Bromodomain inhibitors and cancer therapy: From structures to applications.
Pérez-Salvia M; Esteller M
Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
[TBL] [Abstract][Full Text] [Related]
38. Druggability of methyl-lysine binding sites.
Santiago C; Nguyen K; Schapira M
J Comput Aided Mol Des; 2011 Dec; 25(12):1171-8. PubMed ID: 22146969
[TBL] [Abstract][Full Text] [Related]
39. A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.
Miller TC; Simon B; Rybin V; Grötsch H; Curtet S; Khochbin S; Carlomagno T; Müller CW
Nat Commun; 2016 Dec; 7():13855. PubMed ID: 27991587
[TBL] [Abstract][Full Text] [Related]
40. Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps.
Keck KM; Moquin SA; He A; Fernandez SG; Somberg JJ; Liu SM; Martinez DM; Miranda JL
J Biol Chem; 2017 Aug; 292(32):13284-13295. PubMed ID: 28588024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
